Acorda Therapeutics Inc. (ACOR)

3.49
NASDAQ : Health Technology
Prev Close 3.39
Day Low/High 3.34 / 3.58
52 Wk Low/High 2.27 / 21.63
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 48.08M
Market Cap 162.99M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners

Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners

Cramer says the market's diverse leadership is a very bullish sign.

Acorda Therapeutics Announces Preliminary Tender Offer Results And Acceptance Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. Tendered In Tender Offer

Acorda Therapeutics Announces Preliminary Tender Offer Results And Acceptance Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. Tendered In Tender Offer

On 11 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") commenced a voluntary public tender offer to purchase all of the issued and outstanding shares (" Shares"), American Depositary Shares...

Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting

Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that data from a Phase 2b clinical trial of CVT-301 in Parkinson's disease (PD) will be featured during the Movement Disorders Invited Science Session at the...

Acorda Therapeutics Supplements The Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 22 March 2016

Acorda Therapeutics Supplements The Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 22 March 2016

As announced on 10 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") has on 11 March 2016 commenced a voluntary public tender offer (the " Tender Offer") to purchase all of the issued and...

Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation To Continue In Delaware District Court

Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation To Continue In Delaware District Court

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that Acorda's Abbreviated New Drug Application (ANDA) litigation...

Acorda Therapeutics Supplements Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies On 18 March 2016

Acorda Therapeutics Supplements Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies On 18 March 2016

As announced on 10 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") has on 11 March 2016 commenced a voluntary public tender offer (the " Tender Offer") to purchase all of the issued and...

Acorda Announces Patent Trials And Appeal Board (PTAB) Institutes IPRs Of AMPYRA Patents

Acorda Announces Patent Trials And Appeal Board (PTAB) Institutes IPRs Of AMPYRA Patents

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) has instituted the inter partes review (IPR) of U.

Acorda Therapeutics, Inc. Will Commence The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 11 March 2016

Acorda Therapeutics, Inc. Will Commence The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 11 March 2016

As announced on 19 January 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") and Biotie Therapies Corp.

Acorda Has Filed Tender Offer Document Relating To Public Tender Offer For Biotie Therapies With Finnish Financial Supervisory Authority

Acorda Has Filed Tender Offer Document Relating To Public Tender Offer For Biotie Therapies With Finnish Financial Supervisory Authority

As announced on January 19, 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda") and Biotie Therapies Corp.

Acorda Therapeutics To Present At Two Investor Conferences In March

Acorda Therapeutics To Present At Two Investor Conferences In March

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during March.

Acorda Announces Expiration Of The Hart-Scott-Rodino Waiting Period For Its Tender Offer For Biotie Therapies

Acorda Announces Expiration Of The Hart-Scott-Rodino Waiting Period For Its Tender Offer For Biotie Therapies

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), for its tender offer for Biotie Therapies Corp.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BRKR, GCO, MOS, TOWR Downgrades: ACOR, AF, CFG, CHGG, DISH, DLHC, DVA, ECOL, ETFC, GTIM, HPT, K, NATL, NEWT, NR, OHI, OLP, PPC, RHT, SCSS, SLF, TEO, TRI, TRIP, TRP, VEEV, VG, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2015

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2015

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2015.

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during February.

Acorda To Host Conference Call To Discuss Fourth Quarter And Year End 2015 Results On February 11, 2016

Acorda To Host Conference Call To Discuss Fourth Quarter And Year End 2015 Results On February 11, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter and year end 2015 financial results and pipeline updates on Thursday, February 11 at 8:30 a.

Acorda Therapeutics (ACOR) Stock: Weak On High Volume Today

Acorda Therapeutics (ACOR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a weak on high relative volume candidate

7 Stocks to Trade for Breakouts on Big Volume

7 Stocks to Trade for Breakouts on Big Volume

These stocks trading on unusual volume are within range of triggering breakout trades.

Acorda Acquires Parkinson's Drug Through Biotie Buyout

Acorda Acquires Parkinson's Drug Through Biotie Buyout

Acorda's all-cash tender offer values Biotie at $363 million, or $25.60 per ADS, representing a 96% premium over the stock's closing price on Friday.

European Stocks Follow Asia Higher as China GDP Revives Hopes for Stimulus

European Stocks Follow Asia Higher as China GDP Revives Hopes for Stimulus

European stocks rise on Tuesday, following gains across Asia, as Chinese GDP figures are no worse than expected yet weak enough to revive hopes of government stimulus.

Acorda To Acquire Biotie Therapies

Acorda To Acquire Biotie Therapies

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Biotie Therapies Corp.

Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance And 2016/2017 Clinical Milestones At J.P. Morgan Healthcare Conference

Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance And 2016/2017 Clinical Milestones At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2015 of $121 million.

Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference

Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that it will present at the 34 th Annual J.

Acorda Announces Departure Of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. As Interim CMO

Acorda Announces Departure Of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. As Interim CMO

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Chief Medical Officer (CMO) Enrique Carrazana, M.

Acorda Presents Analyses On Use Of Healthcare Services For Seizure Clusters At American Epilepsy Society Annual Meeting

Acorda Presents Analyses On Use Of Healthcare Services For Seizure Clusters At American Epilepsy Society Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced analyses from a study showing the effect of rescue medication for seizure clusters on both clinical outcomes and healthcare resource utilization.

Acorda Initiates Phase 1 Clinical Trial Of CVT-427, Inhaled Therapy For Acute Treatment Of Migraines

Acorda Initiates Phase 1 Clinical Trial Of CVT-427, Inhaled Therapy For Acute Treatment Of Migraines

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced initiation of enrollment in the first clinical study of CVT-427, an investigational agent under development for the acute treatment of migraines.

Acorda Therapeutics To Present At The Oppenheimer Annual Healthcare Conference

Acorda Therapeutics To Present At The Oppenheimer Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Oppenheimer Healthcare Conference in New York on Tuesday, December 8 at 11:30 am.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: A, ACLS, ACOR, CMCT, COHR, CTRP, GTN, GTN.A, HMHC, IESC, JCTCF, MCBC, NTAP, OKSB, QLGC, RBCAA, SCAI, SPLS, STAY, STS, SVT, TIK, WCIC, WSCI Downgrades: AAN, AKO.A, AREX, CIX, CRM, ESRT, FSBK, FTD, GPRE, JACK Initiations: PINC, VSLR, YUMA Read on to get TheStreet Quant Ratings' detailed report:

Acorda Therapeutics To Present At Two Investor Conferences In November

Acorda Therapeutics To Present At Two Investor Conferences In November

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during November.

Acorda Therapeutics (ACOR) Strong On High Relative Volume Today

Acorda Therapeutics (ACOR) Strong On High Relative Volume Today

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a strong on high relative volume candidate

Acorda Provides Financial And Pipeline Update For 2015 Third Quarter

Acorda Provides Financial And Pipeline Update For 2015 Third Quarter

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the third quarter ended September 30, 2015.

TheStreet Quant Rating: D (Sell)